The hematologic response to anti-apoptotic cytokine therapy: Results of pentoxifylline, ciprofloxacin, and dexamethasone treatment for patients with myelodysplastic syndrome

Journal of Korean Medical Science

Volumn 21, Issue 1, 2006, Pages 40-45

  Kim, Min Kyoung ^a   Lee, Jae Lyun ^b   Cho, Hee Soon ^a   Bae, Sung Hwa ^c   Ryoo, Hun Mo ^c   Lee, Kyung Hee ^a   Hyun, Myung Soo ^a  

^a Yeungnam University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Catholic University of Daegu   (South Korea)

Author keywords

Apoptosis; Myelodysplastic Syndromes; Tumor Necrosis Factor apha

Indexed keywords

EID: 33144474903     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2006.21.1.40     Document Type: Article

References (28)

1. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999; 340: 1649-60.
2. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, Troutt AB, Ledbetter JA, Deeg HJ. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998; 103: 176-88.
3. Allampallam K, Shetty VT, Raza A. Cytokines and MDS. Cancer Treat Res 2001; 108: 93-100.
4. Broxmeyer HE, Williams DE, Lu L, Cooper S, Anderson SL, Beyer GS, Hoffman R, Rubin BY. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. J Immunol 1986; 136: 4457-95.
5. Roodman GD, Bird A, Hutzler D, Montgomery W. Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells. Exp Hematol 1987; 15: 928-35.
6. Means RT Jr, Krantz SB. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest 1993; 91: 416-9.
7. Sato T, Selleri C, Anderson S, Young NS, Maciejewski JP. Expression and modulation of cellular receptors for interferon-gamma, tumour necrosis factor, and Fas on human bone marrow CD34+cells. Br J Haematol 1997; 97: 356-65.
8. Sawanobori M, Yamaguchi S, Hasegawa M, Inoue M, Suzuki K, Kamiyama R, Hirokawa K, Kitagawa M. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 2003; 27: 583-91.
9. Mundle SD, Reza S, Ali A, Mativi Y, Shetty V, Venugopal P, Gregory SA, Raza A. Correlation of tumor nee rosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes. Cancer Lett 1999; 140: 201-7.
10. Peddie CM, Wolf CR, McLellan LI, Collins AR, Bowen DT. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol 1997; 99: 625-31.
11. Raza A, Venugopal P, Genzer S. Pilot study of pentoxifylline and ciprofloxacin with or without dexamethasone produces encouraging results in myelodysplastic syndromes: acute leukemias VII. In: W. Hiddemann, T. Buchner, B. Wormann, et al, eds. Experimental Approaches and Novel Therapies. New York: Springer-Verlag; 1998: 42-51.
12. Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech 2000; 50: 229-35.
13. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-99.
14. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-49.
15. Greenberg P, Cox C, LeBeau MM, Penaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-88.
16. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL. World Health Organization (WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-4.
17. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, du Randt M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P, Zeldis J. Thalidomide produces transfusion independence in longstanding refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98: 958-65.
18. List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 1997; 90: 3364-9.
19. Deeg HJ, Gotlib J, Beckham C, Dugan K, Holmberg L, Schubert M, Appelbaum F, Greenberg P. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia 2002; 16: 162-4.
20. Raza A, Qawi H, Andric T, Dar S, Lisak L, Huang RW, Venugopal P, Gezer S, Gregory SA, Hsu WT, Loew J, Robin E, Rifkin S, Shah R, Divgi A, Taylor R, Grosset A. Pentoxifylline, ciprofloxacin and dexamethasone improve the ineffective hematopoiesis in myelodysplastic syndrome patients; malignancy. Hematology 2000; 5: 275-84.
21. Raza A, Qawi H, Lisak L, Andric T, Dar S, Andrews C, Venugopal P, Gezer S, Gregory S, Loew J, Robin E, Rifkin S, Hsu WT, Huang RW. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 2000; 95: 1580-7.
22. Maciejewski JP, Risitano AM, Sloand EM, Wisch L, Geller N, Barrett JA, Young NS. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol 2002; 117: 119-26.
23. Deeg HJ, Jiang PY, Holmberg LA, Scott B, Petersdorf EW, Appelbaum FR. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res 2004; 28: 1177-80.
24. Raza A, Candoni A, Khan U, Lisak L, Tahir S, Silvestri F, Billmeier J, Alvi MI, Mumtaz M, Gezer S, Venugopal P, Reddy P, Galili N. Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 2004; 45: 2099-104.
25. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, Jones PA, Lubbert M. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2prime;-deoxycytidine (decitabine) treatment. Blood 2002; 100: 2957-64.
26. Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 2004; 22: 1287-92.
27. List A, Beran M, DiPersio J, Slack J, Vey N, Rosenfeld CS, Greenberg P. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic. syndromes. Leukemia 2003; 17: 1499-507.
28. Silverman LR, Demakos EP, Peterson BL, Komblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-40.